[Sneddon-Wilkinson disease: efficacy of intermittent adalimumab therapy after lost response to infliximab and etanercept].

Sneddon-Wilkinson disease (SWD) is a rare chronic neutrophilic dermatosis. The first-line treatment is dapsone but resistance to treatment may sometimes pose a challenge.
We report a multidrug-resistant patient who responded dramatically before gradually losing response to infliximab and then etanercept. Complete remission was again obtained with adalimumab.
Our case confirms the previously reported dramatic efficacy of anti-TNF biological agents in recalcitrant SWD but highlights the possibility of subsequent loss of response. Furthermore, it illustrates the efficacy of adalimumab in this indication.
AuthorsM Versini, F Mantoux, K Angeli, T Passeron, J-P Lacour
JournalAnnales de dermatologie et de vénéréologie (Ann Dermatol Venereol) Vol. 140 Issue 12 Pg. 797-800 (Dec 2013) ISSN: 0151-9638 [Print] France
Vernacular TitleMaladie de Sneddon-Wilkinson échappant à l'infliximab et à l'étanercept: efficacité de l'adalimumab.
PMID24315227 (Publication Type: Case Reports, English Abstract, Journal Article)
CopyrightCopyright © 2013 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept
  • Adalimumab
  • Aged
  • Anti-Inflammatory Agents (pharmacology, therapeutic use)
  • Antibodies, Monoclonal (pharmacology, therapeutic use)
  • Antibodies, Monoclonal, Humanized (pharmacology, therapeutic use)
  • Drug Administration Schedule
  • Drug Resistance
  • Drug Substitution
  • Etanercept
  • Humans
  • Immunoglobulin A (blood)
  • Immunoglobulin G (pharmacology, therapeutic use)
  • Immunosuppressive Agents (pharmacology, therapeutic use)
  • Infliximab
  • Male
  • Monoclonal Gammopathy of Undetermined Significance (complications)
  • Neutrophil Infiltration
  • PUVA Therapy
  • Receptors, Tumor Necrosis Factor (therapeutic use)
  • Skin Diseases, Vesiculobullous (complications, drug therapy, immunology, pathology)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: